Negative Association Between Allopregnanolone and Cerebral Serotonin Transporter Binding in Healthy Women of Fertile Age

Sundström Poromaa, Inger; Comasco, Erika; Bäckström, Torbjörn; Bixo, Marie; Jensen, Peter; Frokjaer, Vibe G

Published in:
Frontiers in Psychology

DOI:
10.3389/fpsyg.2018.02767

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Negative Association Between Allopregnanolone and Cerebral Serotonin Transporter Binding in Healthy Women of Fertile Age

Inger Sundström Poromaa1, Erika Comasco2, Torbjörn Bäckström3, Marie Bixo3, Peter Jensen4 and Vibe G. Frokjaer4,5

1 Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, 2 Science for Life Laboratory, Department of Neuroscience, Uppsala University, Uppsala, Sweden, 3 Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden, 4 Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 5 Mental Health Services Copenhagen, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Allopregnanolone is a metabolite of the sex hormone progesterone, with suggested relevance for female mood disorders. While allopregnanolone and serotonin are known to influence psychological well-being, the molecular and psychological specifics of their relationship are to date poorly understood, especially in women of fertile age who experience regular fluctuations of progesterone across the menstrual cycle. Availability of serotonin in the synaptic cleft is regulated by the serotonin transporter (SERT), which can be imaged in the living human brain by use of positron emission tomography (PET) and the radiotracer [11C]DASB. To evaluate sex-specific allopregnanolone-SERT interactions, the present study investigated the relationship between cerebral SERT availability, serum allopregnanolone levels and psychological well-being in women of fertile age. Brain imaging data, self-reported symptoms of mental distress and emotion regulation, and biobank material from ninety healthy women were available from the Center for Integrated Molecular Brain Imaging (CIMBI) database. Age, BMI, and daylight minutes were included as covariates in the analyses and SERT genotype (5-HTTLPR) was considered a potential confounder. Lower serum allopregnanolone levels were associated with higher SERT binding in the prefrontal cortex. Moreover, allopregnanolone levels were negatively associated with measures of alertness, although this finding was not mediated by prefrontal cortex SERT binding. These findings suggest a link between the typical psychological well-being experienced in the follicular phase when allopregnanolone levels are low and higher SERT in the prefrontal cortex, a region for higher cognitive functions and top-down regulation of emotions.

Keywords: allopregnanolone, brain, mood, PET, serotonin transporter, women, 5HTT
INTRODUCTION

Progesterone is, together with estradiol, one of the ovarian steroid hormones. Progesterone fluctuations are pronounced during the menstrual cycle, but even more extreme variations are noted across pregnancy and postpartum. Increasing evidence suggests that progesterone influences emotion processing in healthy, naturally cycling women (Tofioletto et al., 2014; Comasco and Sundstrom-Poromaa, 2015). So far, earlier work supports worsened emotion recognition, enhanced emotional memory and increased amygdala reactivity at times of luteal phase progesterone levels (van Wingen et al., 2008; Sundstrom Poromaa and Gingnell, 2014). Furthermore, progesterone has been implicated as a causal agent for premenstrual syndrome and premenstrual dysphoric disorder (PMDD) (Sundstrom et al., 1999; Segebladh et al., 2009). However, while it may be assumed that some of these effects are mediated via the progesterone receptor, some of the typical progesterone-induced mood symptoms could equally well be mediated by γ-aminobutyric acid (GABA)-active progesterone metabolites, such as allopregnanolone (Backstrom et al., 2012). Of relevance, allopregnanolone serum concentrations temporarily follow that of progesterone during the menstrual cycle, but with an offset of one to two days (Ottander et al., 2005). Further, whereas progesterone levels increase by 25-fold during the luteal phase, allopregnanolone levels vary by approximately four-fold (Nyberg et al., 2007).

Animal models point to sedative, anxiolytic, anti-convulsant, and neuroprotective properties of allopregnanolone (Kask et al., 2008; Melcangi et al., 2011; Brunton, 2015). In humans, a distinct role of allopregnanolone for female mood disorders has been difficult to delineate, and at present findings point in two directions. First, in pregnant women low levels of allopregnanolone have been associated with depressive symptoms (Hellgren et al., 2014, 2017), and a proof-of-concept study recently demonstrated that allopregnanolone infusion in the postpartum period was able to rapidly alleviate postpartum depressive symptoms (Kanes et al., 2017). On the other hand, in terms of the menstrual cycle-induced mental health problems, the allopregnanolone antagonist sepranolone was recently demonstrated to hold promise as treatment of PMDD (Bixo et al., 2017). These disparities in effect may be explained by differences in underlying pathophysiology, but potentially also by a suggested inverted U-shaped relationship between allopregnanolone and psychological wellbeing (Backstrom et al., 2014). The relationship between allopregnanolone and serotonergic neurotransmission has received little attention in humans, but animal studies have shown that acute administration of fluoxetine increases allopregnanolone levels in the brain of female rats (Fry et al., 2014; Deval et al., 2015) and diminishes their sensitivity to stress (Deval et al., 2015). Clearly, further studies are needed to elucidate the role of allopregnanolone in female mood disorders, and its' relationship with the serotonin system.

Recently, menstrual cycle phase-dependent associations between allopregnanolone and fMRI resting state functional connectivity was demonstrated in healthy women (Syen et al., 2017). In the mid-follicular phase, allopregnanolone levels correlated negatively with resting state functional connectivity between the seed region of the default mode network, the posterior cingulate cortex, and the somatosensory association cortex in the sensorimotor network. In the late luteal phase, among other associations, allopregnanolone levels correlated negatively with connectivity between another region of the default mode network, the medial prefrontal cortex (mPFC), and primary and association visual cortices, but positively with connectivity between the mPFC and the entorhinal cortex in the limbic system (Syen et al., 2017). Moreover, a one-subject longitudinal study found progesterone-dependent modulation of resting state connectivity between the hippocampus and dorsolateral prefrontal cortex (Arelin et al., 2015). Thus, the primary brain regions of choice for this study were the midbrain, pallidostriatum and prefrontal cortex, all important representatives of serotonergic neurotransmission, and amygdala, insula, posterior cingulate and hippocampus for their association to emotion processing and allopregnanolone or progesterone-influenced connectivity.

In terms of molecular imaging of markers of serotonergic neurotransmission, no study to our knowledge has investigated serotonin transporter (SERT) binding in relation to allopregnanolone. Thus, the present study sought to investigate cerebral SERT binding in relation to allopregnanolone serum levels in women of childbearing age. Allopregnanolone serum concentration was expected to negatively associate with SERT availability, and also to influence measures of mood.

MATERIALS AND METHODS

Subjects

Healthy women (age < 50 years) with regular menstrual cycle (23–35 days), BMI < 50 kg/m², and no use of hormonal contraception or therapy, who had undergone PET scanning on a high resolution research tomograph (HRRT) and had a serum sample from the day of the PET scan stored in the CIMBI Biobank (Knudsen et al., 2016) were included in the study. With these criteria, serum samples of 92 women who had undergone [11C]DASB scan were available for the study. Two blood samples could not be analyzed for technical reasons, leaving a study population of 90 healthy women for the [11C]DASB analyses.

Besides exclusion criteria for neuroimaging, we excluded subjects with clinically relevant medical history, such as neurological or psychiatric disorders, and history of severe head trauma, drug or alcohol abuse, or clinically relevant findings on routine blood chemistry were excluded. All participants had normal findings on brain magnetic resonance imaging (MRI) and displayed no psychopathology according to the revised symptom checklist (SCL-90-R) (Derogatis and Savitz, 1999) and the major depression inventory (MDI). The participants have previously been included as healthy volunteers in studies on GnRH agonist treatment (Frokjaer et al., 2015; Macoveanu et al., 2016;
Fisher et al., 2017a), serotonin transporter binding (Fisher et al., 2017b), gastric bypass surgery (Haahr et al., 2015), and functional connectivity (Beliveau et al., 2015). All projects were approved by the Copenhagen Region Ethics Committee (KF-01-2006-20, KF-01-124/04, H-1-2010-085, and H-2-2010-108), and the women provided written informed consent for participation.

Allopregnanolone Analyses
Blood samples were collected on the day of the PET scan. The blood samples were centrifuged immediately after the phlebotomy and plasma was stored at −20°C. Allopregnanolone plasma concentrations were determined by Umeå Neurosteroid Research Center, in one batch, as previously described (Timby et al., 2006). For measurement of allopregnanolone, we used radioimmunoassay (RIA) after a first step involving extraction with diethyl ether and purification by celite chromatography, the latter to reduce cross-reactivity. The antibody used in the RIA had been raised against 3α-hydroxy-20-oxo-5α-pregnan-11-yl carboxymethyl ether coupled with bovine serum albumin (Agrišera AB, Umeå, Sweden). A RackBeta (Wallace, Finland) scintillation counter was used to count the samples. The allopregnanolone detection limit was 25 pg/ml, with intraassay coefficient of variation for of 6.5% and an interassay coefficient of variation of 8.5%.

SERT Imaging
SERT binding was imaged with [11C]DASB-PET during a 90-min dynamic acquisition directly following the bolus injection of the tracer. A Siemens ECAT HRRT scanner (Siemens, Munich, Germany), operating in three-dimensional acquisition mode, with an in-plane resolution of 2 mm, was used to obtain the PET scans. The outcome of the [11C]DASB binding was the ratio between specific binding and non-displaceable binding of the tracer. We used a modified reference tissue model, using cerebellum as a reference region (the vermis part excluded), designed to quantify [11C]DASB (multilinear reference tissue model/multilinear reference tissue model 2) (Ichise et al., 2003), and implemented in PMOD (version 2.9; PMOD Technologies, Zurich, Switzerland). Movement correction was performed by AIR (Woods et al., 1992). The co-registration of the [11C]DASB mean image to the high-resolution T1-weighted MR image was done using SPM8 (Ashburner and Friston, 1997). The exact details on the [11C] DASB imaging has been presented previously (Frokjaer et al., 2009).

Volumes of Interest
Volumes of interest for this study were outlined on the participant’s MRIs, as described previously (Svarer et al., 2005). In order to constrain the number of statistical comparisons we pooled a number of regions. This approach was based on the observation of high correlation of SERT binding between cortical and high-binding subcortical regions (Erritzoe et al., 2010). Thus, an average SERT binding potential was computed for each participant for the prefrontal cortex (computed by pooling orbito-, superior-, and medial- and inferior-frontal cortex), the pallidostriatum (a combined subcortical region), and

RESULTS
As described in Table 1, women were on average young adults, slightly over-weight and healthy from a psychiatric perspective. According to normative allopregnanolone levels (Nyberg et al., 2007), the majority of women was assessed in the follicular phase,
Table 1 | Demographic data, allopregnanolone levels, and \[^{11}C\]DASB binding in the brain.

<table>
<thead>
<tr>
<th></th>
<th>Mean ± SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>27.4 ± 8.2</td>
<td>18–49</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.4 ± 6.3</td>
<td>17.0–43.9</td>
</tr>
<tr>
<td>Allopregnanolone, nmol/l</td>
<td>0.61 ± 0.50</td>
<td>0.13–3.70</td>
</tr>
<tr>
<td>Estradiol, pmol/l</td>
<td>203 ± 130</td>
<td>60–810</td>
</tr>
<tr>
<td>Progesterone, nmol/l</td>
<td>0.2 ± 0.13</td>
<td>0.06–0.8</td>
</tr>
<tr>
<td>Daylight, minutes</td>
<td>739 ± 201</td>
<td>426–1052</td>
</tr>
<tr>
<td>SCL global severity index</td>
<td>0.3 ± 0.2</td>
<td>0.01–1.16</td>
</tr>
<tr>
<td>Total Mood Disturbance score</td>
<td>5.7 ± 20.5</td>
<td>−21–86</td>
</tr>
</tbody>
</table>

\[^{11}C\]DASB BP

| Prefrontal cortex       | 0.38 ± 0.09 | 0.12–0.61 |
| Midbrain                | 2.06 ± 0.29 | 1.22–2.71 |
| Pallidostriatum         | 1.98 ± 0.35 | 1.12–3.02 |
| Total amygdala          | 1.78 ± 0.35 | 0.82–3.04 |
| Total insula            | 0.89 ± 0.14 | 0.42–1.32 |
| Total hippocampus       | 0.71 ± 0.13 | 0.33–1.09 |
| Total posterior cingulate| 0.49 ± 0.10 | 0.16–0.69 |
| Injected dose, MBq      | 571 ± 56   | 360–642  |
| Injected mass per kilo, μg/kg | 0.03 ± 0.04 | 0.00–0.24 |
| Specific activity, GBq/mmol | 177 ± 136 | 10.0–675 |

\[^{11}C\]DASB binding in women of fertile age, slope = –0.038, SD = 0.017, \( p = 0.024 \). Estradiol and progesterone serum concentrations only available in 72 women.

| TABLE 2 | Multiple linear regression analyses on allopregnanolone influence on \[^{11}C\]DASB binding. |
|-----------------|-----------------|-----------------|
| Slope estimate  | SD              | \( \beta \)      | \( p_{adj} \) | \( R^2 \) |
| Prefrontal cortex| –0.038          | 0.017           | –0.248        | 0.024          | 0.06          |
| Midbrain         | –0.070          | 0.048           | –0.149        | 0.147          | 0.16          |
| Pallidostriatum  | –0.172          | 0.006           | –0.302        | 0.005          | 0.10          |
| Total amygdala   | –0.116          | 0.062           | –0.146        | 0.067          | 0.06          |
| Total insula     | –0.072          | 0.025           | –0.300        | 0.005          | 0.11          |
| Total hippocampus| –0.062          | 0.022           | –0.293        | 0.006          | 0.13          |
| Total posterior cingulate| –0.044       | 0.016           | –0.264        | 0.008          | 0.23          |

Models adjusted for age, BMI, daylight minutes on the scanning day, and weighted against rank order of allopregnanolone levels.

82/90 (91.1%). The highest SERT binding levels on average were found in the midbrain and pallidostriatum, whereas the lowest levels were noted in the prefrontal cortex and posterior cingulate (Table 1). Serum allopregnanolone levels were negatively associated with SERT binding in the prefrontal cortex, pallidostriatum, insula, posterior cingulate, and hippocampus (Table 2 and Figure 1). Overall, the models, which also included age, BMI and daylight minutes, explained 6–23% of the variance in SERT binding levels across regions of interest, with the highest explanatory value in the midbrain, and the lowest in the prefrontal cortex (prefrontal cortex: \( \text{slope} = –0.038, \text{SD} = 0.017, \beta = –0.248, \ p = 0.024 \) (Table 2). However, the only allopregnanolone association that survived robust regression was the one with SERT binding in the prefrontal cortex (slope = –0.011, \( \text{SD} = 0.003, \beta = –0.196, \ p < 0.001 \)), whereas the robust regressions between allopregnanolone and SERT binding in the pallidostriatum and hippocampus were in borderline significance (pallidostriatum; slope = –0.162, \( \text{SD} = 0.083, \beta = –0.236, \ p = 0.054 \), hippocampus; slope = –0.049, \( \text{SD} = 0.027, \beta = –0.187, \ p = 0.071 \)). Further, the negative association between allopregnanolone and prefrontal cortex SERT binding remained when also adjusted for estradiol levels (slope = –0.092, \( \text{SD} = 0.029, \beta = –0.359, \ p = 0.002, \ n = 70 \)). Considering 5-HTTLPR genotype, as a proxy of SERT functionality, did not influence any of the above mentioned findings (tested both as first order effects and interactions).

Allopregnanolone levels were negatively correlated with mean reaction latency and percent correct trials in the Simple Reaction Test, Table 3 and Figure 2. Women who reacted slower displayed higher allopregnanolone levels, and similarly, made more errors (Table 3). The path analysis revealed that allopregnanolone exerted a significant direct effect on frontal cortex SERT binding (standardized estimate –0.321, \( \beta = –0.321, \ p = 0.034 \)) and a
point when progesterone and allopregnanolone levels are low, as the women in this study were assessed at a time-

**DISCUSSION**

Mapping of the allopregnanolone-serotonin transporter relationship in women of fertile age demonstrated a negative correlation between peripheral levels of this neuroactive steroid and prefrontal cortex availability of the protein responsible for serotonin re-uptake from the synaptic cleft. The major limitations of this study was that measurements were mostly performed in the follicular phase, and that the study only included healthy women.

Allopregnanolone, produced both by the ovaries and in the brain, acts not only as a transcription regulator but also as a GABA agonist by binding to its site on the GABA receptor A (GABA_A). Allopregnanolone binding to the GABA_A receptor leads to enhanced chloride ion flow and decreased GABA unbinding, which is reflected by increased frequency of inhibitory postsynaptic current and desensitization of the receptor (Wang, 2011). With GABA being the major inhibitory neurotransmitter in the brain, present in one third of all synapses, the effects of allopregnanolone are expected to be widely spread, albeit with some differences, depending on the localization and subunits of the GABA_A receptor (Wang, 2011). As the women in this study were assessed at a time-point when progesterone and allopregnanolone levels are low, the present findings may reflect interactions between SERT and GABA-mediated tonic conductance at the extra-synaptic level, via α_4β_2δ GABA receptors (Wang, 2011). Presence of GABA_A receptors outside the synaptic cleft has been shown in the hippocampal formation and cortex (Wang, 2011), brain regions expressing SERT. Additionally, phasic modulation of neuronal excitability by GABA can be also influenced by synaptic GABA_A receptors found ubiquitously in the brain (Wang, 2011). Clearly, longitudinal investigations will be needed to understand the relationship between serotonergic neurotransmission and fluctuations of allopregnanolone and mood across the menstrual cycle.

The present findings highlight a relationship between allopregnanolone and SERT, particularly in the prefrontal cortex. In this key region for higher cognitive functions and top-down regulation of emotions, GABA as well as serotonergic projections are widespread (Mengod et al., 2015). Some evidence on GABA-serotonin reciprocal modulation may be derived from animal studies (Svensson et al., 2000; Yan, 2002), but human data is scarce. In terms of molecular imaging of markers of serotonergic neurotransmission in relation to progesterone, 5-HT_2A receptor binding was negatively correlated with progesterone at the whole brain level in postmenopausal women (Stein et al., 2014), whereas combined estrogen-progesterone treatment in postmenopausal women was associated with widespread increased cortical 5-HT_2A receptor binding (Moses et al., 2000; Moses-Kolko et al., 2003). However, binding of these two receptors did not correlate with progesterone in another study of pre- and post-menopausal women (Moses-Kolko et al., 2011). To our knowledge, this is the first study investigating SERT binding in relation to the progesterone metabolite allopregnanolone in women of fertile age.

Higher SERT in the presence of low allopregnanolone levels, and independently of estradiol levels, may explain psychological well-being during the follicular phase of the menstrual cycle. In fact, no association of allopregnanolone with mood and stress was found in this group of healthy women, likely because of the healthy state and the limited variation in these measures during the follicular phase. Previously, lower SERT binding has been associated with depression (Parsey et al., 2006; Newberg et al., 2012). Dysregulation of both allopregnanolone and serotonin have been implicated in anxiety, irritability aggressiveness, as well as cognitive impairment (Schule et al., 2014); however, knowledge of their interaction at the molecular level is scarce. While enhancing effects of SSRIs on peripheral allopregnanolone levels have been demonstrated (Uzunov et al., 1996; Griffin and Mellon, 1999; Pinna et al., 2009), effects in the other direction remain to be studied. Additionally, neurotrophic-like functions have been demonstrated for both allopregnanolone and serotonin, though more limited to developmental stages for serotonin (Whitaker-Azmitia, 2001); and brain-derived neurotrophic factor (BDNF) may be one link. The less functional variant of a polymorphism in the brain derived-neurotrophic factor gene (BDNF), but not the short allele of 5-HTTLPR, has for example been associated with decreased fronto-cingulate activity in response to emotional stimuli in PMDD patients in the luteal phase.
In line, no 5-HTTLPR genotype effect was observed in the present study. We found a negative association between allopregnanolone and general alertness, as measured by the Simple Reaction Test. This finding was expected, given the agonistic effects of allopregnanolone on the GABA<sub>A</sub> receptor (Wang, 2011). In line with a direct effect on the GABA<sub>A</sub> receptor, we found no evidence that slower reaction times was mediated by lower SERT binding.

**CONCLUSION**

To conclude, considering strengths and limitations of the study, the present findings add knowledge to our understanding of allopregnanolone-SERT neurochemistry in brain regions regulating cognition and emotion processing of potential relevance for sex-specific psychiatric disorders. Further studies with samples from the luteal phase, and also including women with diagnosed PMDD, are needed before a full interpretation of the allopregnanolone-SERT relationship can be made.

**REFERENCES**


**AUTHOR CONTRIBUTIONS**

IS, EC, and VF were involved in the conception and design of the study. TB, MB, and PJ participated in the acquisition of data. IS and EC did the data analyses. VF, TB, MB, and PJ contributed to the interpretation. IS and EC drafted the manuscript. All authors revised the manuscript critically for important intellectual content and approved the final version of the manuscript.

**FUNDING**

The funding body had no role in the design of the study, collection and analysis of data and decision to publish. IS and EC are supported by the Swedish Research Council. EC was a Marie Sklodowska Curie fellow and received funds from the Swedish Research Council (VR: 2015-00495), EU FP7-People-Cofund (INCA 600398), and SciLifeLab. VF was supported by The Danish Council for Independent Research, The Lundbeck Foundation (Cimbi), and The Capital Region of Denmark, Foundation for Health Research.


Conflict of Interest Statement: IS serve occasionally on advisory boards or act as invited speaker at scientific meetings for MSD, Bayer Health Care, and Lundbeck A/S. VF has received honorarium as speaker for H Lundbeck A/S.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Sundström Poromaa, Comasco, Bäckström, Bixo, Jensen and Frokjaer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.